

Curriculum Vitae

DANA M. ROQUE, MD

Associate Professor, Obstetrics, Gynecology & Reproductive Sciences, Division of Gynecologic Oncology
University of Maryland School of Medicine

Date 07/02/2021

Contact Information

Business Address Department of Obstetrics, Gynecology & Reproductive Sciences, Division of
Gynecologic Oncology
22 S. Greene St, RM S3AX31
Baltimore, MD 21201

Business Phone: (410) 328-2076
Business Fax: (410) 328-8389
Email: droque@som.umaryland.edu

Education

1998-2002 B.S. Chemistry, Duke University (Cum Laude & Graduation with Distinction)
2002-2007 M.D. University of North Carolina at Chapel Hill

Post-Graduate Education and Training

2007-2011 Residency, Magee Womens Hospital-University of Pittsburgh Medical Center
2011-2014 Fellowship, Yale University School of Medicine

Certifications

2010 Fundamentals of Laparoscopic Surgery
2016 American Board of Obstetricians and Gynecologists
2017 American Board of Obstetricians and Gynecologists – Gynecologic Oncology

Medical Licensures

2007 Inactive, Pennsylvania
2011 Inactive, Connecticut
2014 Active, Maryland

EMPLOYMENT HISTORY

Academic Appointments

2011-2014 Instructor, Department of Obstetrics, Gynecology & Reproductive Sciences,
Yale School of Medicine

2014-2021 Assistant Professor, Department of Obstetrics, Gynecology & Reproductive
Sciences, University of Maryland School of Medicine

2021-present Associate Professor, Department of Obstetrics, Gynecology & Reproductive
Sciences, University of Maryland School of Medicine

Professional Society Membership

2005-present American Association for Cancer Research
2005-present American College of Obstetricians and Gynecologists
2011-present American Association of Gynecologic Laparoscopists
2011-present American Society of Clinical Oncology
2011-present Society of Gynecologic Oncology
2012-present International Gynecologic Cancer Society

Honors and Awards

2019, 2020 *Baltimore* magazine Top Doctor

CLINICAL ACTIVITIES

Clinical Expertise

Board-Certified Gynecologic Oncologist

Clinical and research foci include novel therapeutics for gynecologic malignancies, translational sciences, minimally invasive surgery

Scope of Clinical Practice:

Inpatient

2014-present

Gynecologic Oncology Inpatient and On-Call Service, 26 weeks/year 24hr/d

2014-present

Benign Gynecology Inpatient and On-Call Service, 4 weeks/year 24hr/d

Office

2014-present

Stoler Pavillion, Greenebaum Comprehensive Cancer Center, (1 session/wk): chemotherapy/clinical trial visits; outpatient/surgical care

2017-present

Waterloo-Columbia Faculty Physicians, Inc. (0.75 sessions/wk): outpatient/surgical care

2017-2019

Union Hospital of Cecil County (0.25 sessions/wk): outpatient/surgical care

2019-2020

Aiello Breast Clinic, Baltimore-Washington Medical Center (0.25 sessions/wk): outpatient/surgical care

2020-present

University of Maryland Baltimore-Washington Womens Health Associates, Hanover, MD (0.25 sessions/wk): outpatient/surgical care

2020-present

University of Maryland Faculty Physicians, Inc. Redwood Building (1 session/wk); outpatient/surgical care

Operating Room Privileges

2014-present

University of Maryland Medical Center

2015-present

University of Maryland-Upper Chesapeake Medical Center

2017-present

Ambulatory Surgery Center, Waterloo-Columbia

2019-present

University of Maryland Baltimore-Washington Medical Center

2019-present

Veteran's Administration-Baltimore

2019-present

University of Maryland Medical Center-Midtown campus

ADMINISTRATIVE SERVICE

Institutional Service

Leadership & Committees

2015, 2017-present

Interviewer, OB/GYN Residency Program, University of Maryland

2016-present

Director, Centers of Excellence in Minimally Invasive Gynecology, Surgical Review Corporation

2017-present

Member, Clinical Competency Committee, OB/GYN Residency Program, University of Maryland

2018-present

Associate Member, Graduate Faculty, University of Maryland-Baltimore

2018-present

Member, American Cancer Society Institutional Research Grant Committee, University of Maryland

2019-present

Member, Program Evaluation Committee, OB/GYN Residency Program,

2020-present

Member, University of Maryland Dept Initiative to Combat Bias and Inequities

Workgroup

Local

2017

Advocate, Testimony for Maryland Senate Committee re: SB 918 "Health Insurance Coverage of Fertility Preservation Procedures for Iatrogenic Infertility;" subsequently passed then approved by Governor

National Service

Leadership & Committees

2016-2018 Member, Clinical Practice Committee, Society of Gynecologic Oncology
2017-2019 Member, NRG Oncology Rare Tumor Committee
2021-2023 Member, Foundation for Womens Cancer Patient Education Committee
2021-present Big Ten Cancer Research Consortium Correlative Sciences and Gynecologic Working Groups

Peer Review

2010 Journal Reviewer, *Women's Health* (ISSN 1745-5057) (1x/yr)
2014 Journal Reviewer, *BMC Cancer* (ISSN 1471-2407) (1x/yr), *Cancer* (ISSN 1097-0142) (1x/yr)
2015 Journal Reviewer, *Pharmaceuticals* (ISSN 1424-8247) (1x/yr), *Immunotherapy* (ISSN 1750-743X; 1750-7448) (1x/yr), *BMC Womens Health* (ISSN 1472-6874) (1x/yr), *BMC Cancer* (ISSN 1471-2407) (1x/yr)
2016 Journal Reviewer, *Scientific Reports* (ISSN 2045-2322) (1x/yr), *Cancer Letters* (ISSN: 1872-7980) (1x/yr), *Cancer Chemotherapy and Pharmacology* (ISSN: 0344-5704) (1x/yr), *BMC Cancer* (ISSN 1471-2407) (1x/yr)
2017 Journal Reviewer, *Cancer Chemotherapy and Pharmacology* (ISSN: 0344-5704) (1x/yr), *British Journal of Cancer* (ISSN 0007-0920) (1x/yr)
2018 Journal Reviewer, *Critical Reviews in Oncology & Hematology* (ISSN: 1040-8428) (1x/yr), *American Journal of Obstetrics and Gynecology* (ISSN: 0002-9378) (1x/yr)
2019 Journal Reviewer, *JNCCN* (ISSN:1540-1413) (1x/yr), *PLoS ONE* (eISSN: 1932-6203) (1x/yr)
2020 Journal Reviewer, *Cancer Medicine* (ISSN: 2045-7634) (1x/yr), *Annals of Translational Medicine* (ISSN: 2305-5847) (1x/yr)
2021 Journal Reviewer, *Gynecologic Oncology* (ISSN: 0090-8258) (1x/yr)

International Service

Peer Review

2020 Grant Reviewer, Komop tegen Kanker (Stand Up to Cancer) Flemish Cancer Society) "Rational approach for immunotherapy in ovarian cancer"

TEACHING SERVICE

Undergraduate Student Teaching

2002 Course Instructor, English Immersion Program. Huazhong University of Science and Technology, Wuhan, China, Summer Term
2002 Course Instructor, Rural Healthcare and Community Action. Duke University, Durham, NC, Fall Term

Medical Student Teaching

2015-present Small Group Instructor, Case Discussions: endometrial, cervical, ovarian cancers. 3rd year medical student clerkship, University of Maryland School of Medicine, Baltimore, MD. (1-2x/semester, 20 students per rotation)
2015-present Rotation Preceptor, 3rd year medical student clerkship, University of Maryland School of Medicine, Baltimore, MD. Small group meetings weekly and review of videotaped OSCE [Objective Structured Clinical Examinations] (6 weeks annually, 3-4 students)
2016-present Small Group Instructor, 2nd year medical student course 'Pathophysiology & Therapeutics II-Genitourinary,' University of Maryland School of Medicine, Baltimore, MD. Gynecologic Cancer Cases (endometrial, cervical, ovarian) in conjunction with Pathology staff (2 hours every April, 40 students)

Resident Teaching

2015-present Lecturer, OB/GYN Residency Lecture Series (1-hour each, 30 residents, 2-yr rotating curriculum including

- Basics of Radiation Therapy. Apr 14, 2017
- Principles of Chemotherapy Oct 06, 2017
- Peri-op Antibiotic Prophylaxis. Feb 22, 2018
- Lasers Apr 06, 2018
- Ovarian Cancer Feb 28, 2020
- CREOG review annual

2016-present Instructor, Resident Mock Oral and Skills Exams, OB/GYN Residency Lecture, University of Maryland Medical School (2x/yr)

2016 Lecturer, General Surgery Educational Series, Adnexal Mass, University of Maryland School of Medicine.

2017-present Organizer, MASTRI Surgical Curriculum, OB/GYN Residency Program, University of Maryland (review of FLS curriculum using trainers for 1 hr majority of Fridays, coordination of lectures and wet labs)

Fellow Teaching

2017-present Lecturer, Hematology/Oncology Fellowship Program Lecture Series, University of Maryland School of Medicine, Baltimore, MD (18 fellows)

- uterine cancer (1 hr/yr)
- cervical cancer (1 hr/yr)
- ovarian cancer (1 hr/yr)

Post-Graduate Teaching

2017-present Lecturer, GPLS 665. Cancer Biology-Research to Clinic: Ovarian Cancer. Fall Semester. University of Maryland-Baltimore. Baltimore, MD (1.5 hours 1x/yr, 10-15 students)

2018 Member, Thesis Committee for Masters Candidate Lora Stojanovic: "DNA Methyltransferase Inhibitors in Combination with PARP inhibitors Generate Synthetic Lethality in BRCA-proficient Ovarian Cancer"

2018-2019 Capstone Advisor, Masters of Public Health, Mazine Anjorin, MBBS. "Impacts of Patient Navigation Services on Cancer Preventive Services and Treatment Compliance"

2021-present Member, Thesis Proposal Committee for PhD Candidate Aaron Sorrin

GRANT SUPPORT

Active Grants

04/01/21-03/31/26 (Roque/Zhang, subaward) PI: Huang Chiao-Huang, PhD
NIH R01: "Addressing Chemoresistance in Pancreatic and Ovarian Cancers: Photodynamic Priming and Repurposing of Tetracyclines using Targeted Photo-Activable Multi-Inhibitor Liposome"
NIH R01 PA-19-056

Completed Grants/Fellowships

06/01/05-05/31/06 (Awardee) PI: Elise Kohn, MD, Senior Investigator, Molecular Signaling Section Cancer Research Training Award, National Institutes of Health, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
Total/Annual Stipend: NCI category 2 stipend
Experience in translational research and laboratory techniques (collection/preservation of patient plasma and core needle biopsy samples, laser capture microdissection, analysis of reverse-phase protein microarrays, immunoprecipitation, mass spectroscopy)

06/14/16-02/13/19 (M-PI) PIs: Tatiana Sanses, MD, Vadim Morozov, MD; Minhaj Siddiqui, MD, Shamus Carr, MD
"Multi-Specialty Robotic Simulator Research Program at University of Maryland School of Medicine, Baltimore, MD"

Intuitive Surgical Research Simulator Loan Program
Total/Annual Direct Costs: dVSS system on loan to institution
Recruitment and analysis of resident and attending performance data for gynecology objectives

- 10/01/16-09/30/17 (Co-PI) Co-PI: Jocelyn Reader, PhD
"Tubulin Isotype and Microtentacle Composition in Progression of Ovarian Clear Cell Carcinoma"
Departmental Grant, Obstetrics, Gynecology, and Reproductive Sciences, University of Maryland School of Medicine, Baltimore, MD
Total/Annual Direct Costs: \$50,000
Concept design, data analysis and interpretation
- 04/01/19-03/31/20 (Co-PI) Co-PI: Huang Chiao-Huang, PhD
"Nanotechnology-Assisted, Mechanism-Based Combination Therapy for Ovarian Cancer Peritoneal Carcinomatosis"
Foundation for Women's Cancer (FWC), Caring Together, NY, Ovarian Cancer Research Grant
Total/Annual Direct Costs: \$25,000
Provision of ovarian cancer specimens and access to animal models
- 01/01/19-12/31/20 (Co-PI) Co-PI: Jocelyn Reader, PhD
"Nanotechnology-Assisted, Mechanism-Based Combination Therapy for Peritoneal Carcinomatosis in Low-Grade Serous Ovarian Carcinoma"
Departmental Grant, Obstetrics, Gynecology, and Reproductive Sciences, University of Maryland School of Medicine, Baltimore, MD
Total/Annual Direct Costs: \$50,000
Concept design, data analysis and interpretation
- 01/01/19-12/31/20 (Co-PI) Co-PI: Jiayuh Lin, PhD
"HuR Inhibition as a Novel Approach to Treatment of Chemotherapy-Resistant Low-Grade Serous Ovarian Carcinomas"
Departmental Grant, Obstetrics, Gynecology, and Reproductive Sciences, University of Maryland School of Medicine, Baltimore, MD
Total/Annual Direct Costs: \$50,000
Concept design, data analysis and interpretation

Active Research Protocols

- 12/08/14-present (PI)
"HP-00061641 (1488GCC): Collection of Tissue Samples from Women with Gynecologic Malignancies and Healthy Controls for Laboratory Research"
- 12/08/14-present (PI)
"HP-00061673 (1489 GCC): Treatment and Survival Outcomes for Patients with Gynecologic Malignancies"
- 06/03/15-present (PI)
"HP-00063498 (GCC1543): Molecular Profiling of Gynecologic Cancers"
- 06/14/16-present (Co-PI)
"HP-00066154: TERPS (Training, Education, and Robotic Performance with Simulation) at University of Maryland Medical Center"
Sponsor: Intuitive Surgical, Inc.
- 01/25/19-present (PI/Mentor of resident research project for Kylie Klein, MD)
"HP-00082189 (18121GCC): Characterization of Pap Smear Trends in HIV Positive Women and Healthy Controls"

Completed Research Protocols

09/25/18-09/22/19

(PI/Capstone Advisor for MPH student Mazine Anjornin, MBBS)
"HP-00081003 (18116GCCC): Impacts of a Patient Navigator"

Active Clinical Trials

01/18/19-present

(Site PI)
"HP-00082352 (18111GCCC): TESARO FIRST A Phase 3 Trial with TSR-042 and Niraparib vs SOC in Non-Mucinous Epithelial Ovarian Cancer"
Sponsor: Tesaro, Inc.

05/02/19-present

(Site PI)
"HP- 00084982 (1924GCCC): GOG 3018/OVAL, A Study of VB-111 with Paclitaxel versus Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer"
Sponsor: Vascular Biogenics, Ltd.

01/13/20-present

(Site PI)
"HP-00088558, NRG-GY018: Testing the Addition of the Immunotherapy Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer"
Sponsor: National Cancer Institute

04/13/20-present

(Site PI)
"HP-00088476, NRG-GY0019: Testing Hormonal Drug Letrozole Alone or in Addition to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Low-grade Serous Ovarian or Peritoneal Cancer"
Sponsor: NRG Oncology

01/06/21-present

(Site PI)
"HP-00093504, NRG-CC008: A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer"
Sponsor: NRG Oncology

03/31/21-present

(Site PI)
"HP-2135GCCC: A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma"
Sponsor: K-Group Beta

Completed Clinical Trials

06/06/11-06/01/20

(Site PI)
"HP-00061901 (1467GCC) Randomized Phase II Evaluation of Carboplatin / Paclitaxel +/- Trastuzumab in HER2/Neu+ Advanced or Recurrent Uterine Papillary Serous Carcinoma"
Sponsor: Yale University / Genentech
Total Awarded: \$50,000 (Direct: \$38,461.34, Indirect: \$11,538.46)

07/24/17-07/01/20

(Site PI)
"HP-00074863 (1730GCCC): A Randomized Phase II Evaluation of Weekly Ixabepilone with or without Biweekly Bevacizumab"
Sponsor: Yale University / R-Pharm-US, LLC
Total Awarded: \$25,185.15 (Direct: \$19,380, Indirect: \$5,805.09)

PUBLICATIONS

Peer Reviewed Journal Articles

1. **Roque DM** (ed). Perinatal ethics. *Virtual Mentor: American Medical Association Journal of Ethics* 2007; 9: 597-659. Available at <http://virtualmentor.ama-assn.org/2007/09/toc-0709.html>.

2. **Roque DM**, Wang SA, Wasley A, Jacques-Carroll L, Roush S, Weinbaum CM on behalf of the CDC. Assessing completeness of perinatal hepatitis B virus infection reporting through comparison of immunization program and surveillance data — United States. *Morbidity and Mortality Weekly Report* 2011; 60(3): 410-3.
3. Carrara L, Guzzo F, **Roque DM**, Bellone S, Cocco E, Sartori E, Pecorelli S, Schwartz PE, Rutherford TJ, Santin AD. Differential *in vitro* sensitivity to paclitaxel versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression. *Gynecologic Oncology* 2011; 125(1): 231-6.
4. Bellone S, **Roque DM**, Cocco E, Gasparrini S, Bortolomai I, Buza N, Abu-Kalaf M, Silasi D, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Down-regulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitizes uterine serous carcinoma overexpressing Her2/Neu to complement and antibody-dependent cell cytotoxicity *in vitro*: implications for trastuzumab-based immunotherapy. *British Journal of Cancer* 2011; 106(9): 1543-50.
5. Bignotti E, Zanotti L, Calza S, Falchetti M, Lonardi S, Ravaggi A, Romani C, Bandiera E, Tassi RA, Facchetti F, Sartori E, Pecorelli S, **Roque DM**, Santin AD. Trop-2 protein overexpression is an independent prognostic marker for disease recurrence in endometrioid endometrial carcinoma. *BMC Clinical Pathology* 2012 12(1): 22-30.
6. Zhao S, Choi M, Overton JD, Bellone S, **Roque DM**, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. *Proceedings of the National Academy of Science* 2013; 110(8): 2916-21.
7. **Roque DM**, Bellone S, English DP, Buza N, Cocco E, Gasparrini S, Bortolomai I, Ratner E, Silasi D, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Tubulin- β -III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. *Cancer* 2013; 119(14): 2582-92.
8. Bignotti E, Tassi RA, Calza S, Ravaggi A, Rossi E, Donzelli C, Todeschini P, Romani C, Bandiera E, Zanotti L, Carnazza M, Quadraro F, Tognon G, Sartori E, Pecorelli S, **Roque DM**, Santin AD. Secretoglobulin expression analysis in epithelial ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. *Journal of Translational Medicine* 2013; 11(1): 162.
9. **Roque DM**, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD. Tubulin- β -III overexpression in ovarian clear cell and serous carcinoma as a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to paclitaxel. *American Journal of Obstetrics & Gynecology* 2013; 209(1): 62.e1-9.
10. English DP, **Roque DM**, Carrara L, Lopez S, Bellone S, Cocco E, Bortolomai I, Schwartz PE, Rutherford TJ, Santin AD. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. *Gynecologic Oncology* 2013; 131(3):753-8.
11. **Roque DM**, Buza N, Glasgow M, Bellone S, Bortolomai I, Gasparrini S, Cocco E, Ratner E, Silasi D, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Class III β -tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. *Clinical & Experimental Metastases* 2014; 31(1): 101-10.
12. Schwab CL, M.D, English DP, **Roque DM**, Bellone S, Lopez S, Cocco E, Nicoletti R; Rutherford TJ, Schwartz PE, Santin AD. Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma *in vitro* and *in vivo*. *Gynecologic Oncology* 2014 doi: 10.1016/j.ygyno.2014.08.006.
13. Schwab CL, Bellone S, English DP, **Roque DM**, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Afatinib demonstrates remarkable activity against HER2 amplified uterine serous endometrial cancer *in vitro* and *in vivo*. *British Journal of Cancer* 2014; 111(9):1750-6.
14. English DP, Bellone S, Schwab CL, **Roque DM**, Lopez S, Bortolomai I, Cocco E, Bonazzoli E, Chatterjee S, Ratner E, Silasi DA, Schwartz PE, Rutherford TJ, Santin AD. Solitomab, an EpCAM/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy resistant ovarian cancer cell lines *in vitro* and fresh tumor cells *ex vivo*. *Cancer* 2014; doi: 10.1002/cncr.29062.
15. **Roque DM**, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Nelson W, Santin AD. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review. *Gynecologic Oncology* 2015; 137(3):392-400.
16. Cohen J, Harper A, Nichols EM, Rao GG, Mohindra P, **Roque DM**. Barriers to timely completion of radiation therapy in patients with cervical cancer in an urban tertiary care center. *Cureus* 2017; 9(9): e1681. DOI 10.7759/cureus.1681.

17. Ramaseshan AS, Felton J, **Roque D**, Rao GG, Shipper AG, Sanses TVD. Pelvic floor disorders in women with gynecologic malignancies: a systematic review. *International Urogynecology Journal* 2017; 29(4):459-76.
18. Fader AN, **Roque DM**, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord A, Havrilesky L, O'Malley D, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Azodi M, Litkouhi B, Ratner E, Silasi D, Schwartz PE, Santin AD. Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-trastuzumab (CP-T) in advanced (stage III-IV) or recurrent uterine serous carcinoma overexpressing *Her2/Neu* (NCT1367002). *Journal of Clinical Oncology* 2018; 36(20):2044-51
19. Reader J, Harper A, Legesse T, Staats PN, Goloubeva O, Rao GG, Fulton A, **Roque DM**. EP4 and class III β -tubulin expression in uterine smooth muscle tumors: implications for prognosis and treatment. *Cancers* (Basel) 2019;11(10): pii: E1590. doi: 10.3390/cancers11101590.
20. Fader AN, **Roque DM**, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley D, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Santin A, Bellone S, Litkouhi B, Ratner E, Silasi DA, Schwartz P, Santin AD. Randomized phase II trial of carboplatin–paclitaxel compared with carboplatin–paclitaxel–prastuzumab in advanced (stage III–IV) or recurrent uterine serous carcinomas that overexpress *Her2/Neu* (NCT01367002): updated overall survival analysis. *Clinical Cancer Research* 2020; DOI: 10.1158/1078-0432.CCR-20-0953.
21. Zhang R, Yang X, **Roque DM**, Li C, Lin J. A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin. *PLoSOne* 2021; 28;16(4):e0240145. doi: 10.1371/journal.pone.0240145.

Submitted or In-Revision Peer-Reviewed Journal Articles

1. Helou C, Seal P, Sanses TVD, Morozov V, **Roque DM**. Training, Education for Robotic Performance with Simulation (TERPS): a valuable tool for gynecologic surgeons in training. *Journal of Minimally Invasive Gynecology* (submitted).
2. Klein KL, Goron AR, Taylor GH, **Roque DM**. Pap Smear outcomes in older HIV-positive women and HIV-negative matched controls. *Infectious Diseases in Obstetrics and Gynecology* (submitted).
3. Dorismond VG, Bui B, **Roque DM**, Sanses TVD. Robotic performance with simulation among robotic surgeons with low and high surgical volumes at an academic medical center. *American Journal of Obstetrics & Gynecology* (submitted).
4. Bellone S, **Roque DM**, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D-A, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin AD. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high endometrial cancer patients with Lynch-like vs MLH-1 methylated characteristics (NCT02899793). *Cancer* (in revision).
5. **Roque DM**, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader J, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. *British Journal of Cancer* (submitted).
6. Zhang R, Fu S, Chen X, **Roque DM**, Reader J, Spencer W, Aubé J, Wu X, Xu L, Lin J. A novel small molecule HuR inhibitor KH-3 exhibits potent growth-suppressive activity and enhances the effect of chemotherapy in human ovarian cancer cells. *Journal of Pharmacology and Experimental Therapeutics* (submitted).
7. Baglo Y, Sorrin AJ, Xiaocong Pu, Liu C, Reader J, Robey R, **Roque DM**, Gottesman MM, Huang H-C. Evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy. *Cancer Letters* (submitted).
8. Duru N, Pawar NR, Martin EW, Buzza MS, Conway GD, Lapidus RG, Liu S, Reader J, Rao G, **Roque DM**, Leppla SH, Antalis TM. Targeting metastatic ovarian cancer using a novel engineered anthrax prodrug activated by membrane serine proteases. *Cancer Discovery* (submitted 04/2021).
9. Sorrin A, Liu C, Cicalo J, Reader J, Najafali D, Zhang Yuji, **Roque DM**, Huang HC. Photodynamic priming coupled with co-inhibition of EGFR and EP4 signaling attenuates metastatic behavior in ovarian cancer cells (in preparation).
10. Pollock AE, Risher H, Sun K, Oza I, Marter K, Alicia D, Rao G, **Roque DM**, Nichols EM, Mohindra P. Clinical outcomes and dosimetric data for patients with gynecologic malignancies: a comparison between a proton and photon matched cohort. American Radiation Society Annual Meeting 2021 (submitted).
11. Pollock AE, Risher H, Bentzen SM, **Roque DM**, Rao G, Nichols EM, Mohindra P. Clinical outcomes of patients treated with intensity modulated proton therapy (IMPT) re-irradiation for gynecologic malignancies. American Society for Radiation Oncology Annual Meeting 2021 (submitted).

Peer-Reviewed Case Reports, Technical Notes, Letters

1. **Roque DM**, Jones D, Carter G, Kelley JL. Primary giant cell malignant fibrous histiocytoma of the ovary: case report and review of the literature. *Gynecologic Oncology* 2010; 119(2): 397-8.
2. **Roque DM**, Azodi M. *Robotic Surgery: Research and Reviews* 2014 [editorial forward]; 1: 11-12.
3. Dick-Biascoechea M, **Roque DM**, Schwartz PE. Appearances can be deceiving: ovarian mass presents as vaginal prolapse. *American Journal of Obstetrics and Gynecology* 2014; 211(3):310.e1-2.
4. Miller D, **Roque DM**, Santin AD. The use of Monsels' solution to treat obstetrical haemorrhage: a review and comparison to other topical hemostatic agents. *American Journal of Obstetrics & Gynecology* 2015; 212(6):725-35.
5. Black J, **Roque DM**, Pasternac MC, Buza N, Rutherford TJ, McCarthy S, Ratner E. A series of malignant ovarian cancers arising from within a mature cystic teratoma: a single institution experience. *International Journal of Gynecologic Cancer* 2015 25(5):792-7.
6. Kapoor K, Evans MC, Shkullaku M, Schillinger R, White CR, **Roque DM**. Biventricular metastatic invasion from cervical squamous cell carcinoma. *BMJ Case Reports* 2016; doi: 10.1136/bcr-2016-214931.
7. **Roque DM**, Santin AD. Oncofertility in gynecologic oncology: an oxymoron? *Future Oncology* 2016; 12(14):1683-6.
8. **Roque DM**, Santin AD. Uterine cancer, mutational phenotype, and the era of immune checkpoint blockade. *Expert Review Clinical Immunology* 2016 [editorial]. PMID: 27905822. Available at <http://dx.doi.org/10.1080/1744666X.2017.1266938>.
9. Mayer R, Dandulakis M, Richards S, **Roque DM**, Staats PN. Malignant sex-cord stromal tumor, not otherwise specified, harboring FOXL2, p53, and TERT promoter mutations: report of a case. *International Journal of Gynecologic Pathology* 2019; doi: 10.1097/PGP.0000000000000651.

Peer-Reviewed Reviews

1. **Roque DM**, Sherman F. Review: 'Heart Disease in Pregnancy.' *Journal of Pediatric and Adolescent Gynecology* 2008; 21(5): 301-2. doi:10.1016/j.jpag.2007.12.006.
2. **Roque DM**, Schwartz PE, Santin AD. Targeted therapy for high-risk endometrial cancer. *Clinical Practice* 2012; 9(5): 539-54
3. **Roque DM**, Santin AD. Updates in therapy for uterine serous carcinoma. *Current Opinion in Obstetrics & Gynecology* 2013; 25(1): 29-37.
4. English DP, **Roque DM**, Santin AD. Class III β -tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents? *Expert Reviews of Anticancer Therapy* 2013; 13(1): 63-74.
5. English DP, **Roque DM**, Santin AD. HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. *Molecular Diagnosis and Therapy* 2013; 17(2): 85-99.
6. Schwab CL, English DP, **Roque DM**, Santin AD. Taxanes: impact on gynecologic malignancies. *Anti-Cancer Drugs* 2014; 25(5):522-35.
7. Buza N, **Roque DM**, Hui P, Santin AD. Her2/Neu in endometrial cancer: a promising therapeutic target and diagnostic challenge. *Archives of Pathology and Laboratory Medicine* 2014; 138(3):343-50.doi: 10.5858/arpa.2012-0416-RA.
8. Black J, English DP, **Roque DM**, Santin AD. Targeted therapy in uterine serous carcinoma, an aggressive variant of endometrial cancer. *Women's Health* 2014; 10(1):45-57.
9. Schwab CL, English DP, **Roque DM**, Pasternak M, Santin AD. The past, present, and future role of immunotherapy in ovarian cancer. *Immunotherapy* 2014;6(12):1279-93.
10. Lynam S, Young L, Morozov V, Rao G, **Roque DM**. Risk, risk reduction, and management of occult malignancy diagnosed after uterine morcellation: a commentary. *Womens' Health (Lond Engl)* 2015; 11(6): doi 10.2217/WHE.15.63.
11. Molitoris JK, Diwanji T, Samanta S, Lamichhane N, Chhabra A, **Roque D**, Rao G, Amin P, Nichols E, Mohindra P. Improving outcomes through immune system modulation in the treatment of gynecological malignancies. *Reproductive Immunol Open Acc* 2017; 2(3): 34.
12. Fan C, Reader J, **Roque DM**. Review of immune therapies targeting ovarian cancer. *Current Treatment Options in Oncology* 2018;19(12):74. doi: 10.1007/s11864-018-0584-3.
13. Smith P, **Roque DM**, Ching McMillan N, Fulton A, Rao GG, Reader JC. Eicosanoids in gynecologic malignancies. *Frontiers in Pharmacology* 2020; doi: 10.3389/fphar.2020.01233.

Chapters

1. Annunziata C, **Roque DM**, Azad N, Kohn EC. Chapter 5: Application of serum and tissue proteomics to understand and detect solid tumors. In *Cancer Proteomics: From Bench to Bedside*, Sayed S. Daoud, ed. Totowa, NJ: Humana Press, ©2008, pp 101-120.
2. **Roque DM**, Santin AD. Antigen-specific immunotherapy for ovarian cancer. In *Advances in Ovarian Cancer Management*, Peter Schwartz, ed. ISBN (epub) 978-1-78084-081-9, © 2012.
3. **Roque DM**, Santin AD, Schwartz PE. Multidisciplinary management of serous carcinoma of the endometrium. In *Current Multidisciplinary Oncology: Gynecologic Cancers*, Kunle Odunsi and Tanja Pejovic, eds, 1st edition. NY: Demos Medical, © 2013, ISBN: 978-1936287895.
4. English DP, **Roque DM**, Buza N, Santin AD. HER2 as a biomarker for endometrial cancer. In *Biomarkers in Disease: Methods, Discoveries and Applications*, Victor R. Preedy & Vinood B. Patel, eds., c.2015.
5. Black J, **Roque DM**, Gold L, Santin AD. Future directions and new targets in endometrial cancer. In *Current Clinical Oncology*, Springer International Publishing, c.2015.
6. Reader J, Lynam S, Harper A, Rao GG, Matheny M, **Roque DM**. Ovarian tumor microenvironment and innate immune system. In *Ovarian Cancer Immunotherapy*, Samir Farghaly, ed. ISBN: 97801902, Oxford University Press, ©2018.
7. Klein K, Dandulakis M, **Roque DM**. Principles of cytotoxic chemotherapy. In *Advanced in Diagnosis and Management of Ovarian Cancer*, Samir Farghaly, ed. ISBN: 978-1461482703, New York: Springer, © 2020 [in press August 2020].

Major Invited Speeches

Local

1. Special Problems in the Use of Blood Products in Obstetrics and Gynecology. Grand Rounds, Magee Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, 2010
2. Gynecologic Malignancies. Mini-Medical School Program, University of Maryland School of Medicine, Baltimore, MD, 2015
3. Class III β -Tubulin: Insights into Paclitaxel Resistance and Sensitivity to Etoposides in Gynecologic Malignancies. Hematology/Oncology Grand Rounds, University of Maryland School of Medicine, Baltimore, MD, 2015
4. Chemotherapy for Gynecologic Malignancy: from serendipity to personalized molecular medicine. Grand Rounds, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Maryland School of Medicine, Baltimore, MD, 2016
5. Cancer in Pregnancy. Signature OB/GYN, Columbia, MD, 2017
6. Class III β -Tubulin: Role in Gynecologic Malignancies. Hormone Responsive Cancers Annual Retreat, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, 2017
7. Cervical Cancer in 2018: Tragedy or Success? CME Program at Union Hospital of Cecil County, Elkton, MD, 2018
8. Updates in Minimally Invasive Surgery for Cervical Cancer & Quality Control/Training Initiatives for Minimally Invasive Gynecology. Tate Cancer Center 3rd Annual Minimally Invasive Cancer Care Symposium, Baltimore-Washington Medical Center, Glen Burnie, MD, 2019
9. Cancer Survivorship for the Generalist OB/GYN. Grand Rounds. St. Agnes OB/GYN Group (virtual), 03/24/2021.

Abstracts and/or Proceedings

Oral Presentations-Local

1. **Roque DM**, Mantia-Smaldone GM, Lenzner D, Edwards RP. Prognostic variables for patients receiving neoadjuvant chemotherapy for advanced ovarian and peritoneal cancers. Mid-Atlantic Gynecologic Oncology Society, 24th Annual Meeting, Hot Springs, VA, October 9-10, 2009.
2. **Roque DM**, Mantia-Smaldone GM, Lenzner D, Zorn KK, Sukumvanich P, Kelley JL, Edwards RP. Correlation of biomarker responses with surgical outcome and survival following neoadjuvant chemotherapy for advanced ovarian and primary peritoneal cancers. 2010 Annual Research Day in Reproductive Biology and Women's Health, Magee Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, June 4, 2010.
3. **Roque DM**, Bellone S, Buza N, Cocco E, Gasparinni S, Bignotti E, Ravaggi A, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD. Tubulin- β -III overexpression is a marker of sensitivity to etoposides in ovarian clear cell carcinoma. New England Association of Gynecologic Oncologists, 32nd Annual Meeting. Bar Harbor, ME, June 6-8, 2012.

4. **Roque DM**, Bellone S, Buza N, Cocco E, Gasparinni S, Ratner E, Silasi DA, Azodi M, Thomas J, Rutherford, Peter E, Schwartz, Alessandro D, Santin. Tubulin- β -III overexpression is a marker of sensitivity to epothilones in ovarian clear cell carcinoma. New England Association of Gynecologic Oncologists, 32nd Annual Meeting. Bar Harbor, ME, June 6-8, 2012.
5. **Roque DM**, Ratner ES, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Weekly ixabepilone with or without concurrent bevacizumab in the treatment of platinum/taxane-resistant endometrial and ovarian cancers: an institutional experience. New England Association of Gynecologic Oncologists, 33rd Annual Meeting, Westbrook, CT, June 14-16, 2013.
6. Cohen J, Harper A, **Roque DM**, Rao GG, Mohindra P, Nichols E. Barriers to timely completion of radiation therapy in patients with cervical cancer in an urban tertiary care center. Annual Meeting of the Mid-Atlantic Gynecologic Oncology Society, Baltimore, MD, October 13-15, 2016.
7. Harper A, Legesse T, **Roque DM**, Rao GG, Staat PN, Fulton A, Reader J. EP4 receptor and class III- β tubulin expression in uterine smooth muscle tumors: implications for prognosis and treatment. Annual Meeting of the Mid-Atlantic Gynecologic Oncology Society, Baltimore, MD, October 13-15, 2016.

Oral Presentations-National

8. **Roque DM**, Roush SW, Jacques-Carroll L, Wasley A, Wang S. Evaluation of perinatal hepatitis B virus (pHBV) infections reported to the National Notifiable Disease Surveillance System (NNDSS) for infants born in 2005. National Immunization Conference, 42nd Annual Meeting, Atlanta, GA, March 20, 2008. Available at <http://cdc.confex.com/cdc/nic2008/webprogram/Paper15581.html>.
9. Nichols E, Bentzen S, Daniels I, Rao G, **Roque DM**, Hanna N, Mohindra P. National cancer database analysis of uterine carcinosarcoma: improvement in survival with the use of radiation therapy.
 — American Society for Radiation Oncology, 58th Annual Meeting, Boston, MA, Sept 25-28, 2016.
 — Best of ASTRO Meeting, Ft. Lauderdale, FL, November 11-12, 2016.
10. Santayana S, Sun W, Yang P, Dick M, Johnson HW, Fan C, Reader J, Shen W-B, Fulton A, Yang P, **Roque DM**. EP4 receptor expression in pelvic organ prolapse and radiation-induced vaginal stenosis: a novel therapeutic target. American Urogynecologic Society, Chicago, IL, October 9-13, 2018.
11. **Roque DM**. Training, Education for Robotic Performance with Simulation at University of Maryland Medical Systems. Education and Training Research Grant Symposium. Sunnyvale, CA, January 18, 2018 (WebEx) & February 01, 2019 (Sunnyvale, CA).
12. Dandulakis M, Reader J, Smith P, Fan C, Carey M, Lin J, Liang Xu, Legesse T, Ioffe O, Rao G, Fulton A, **Roque DM**. HuR inhibition is a novel approach to treatment of chemotherapy-resistant low-grade serous ovarian carcinomas. Mid-Atlantic Gynecologic Oncology Society 2019 Annual Meeting, Charlotte, NC, Oct 24-26, 2019.
13. Nickles-Fader A, **Roque DM**, Eric Diegel, Natalia Buza, Pei Hui, Laura Havrilesky, Angeles Secord, David M. O'Malley, Flor Backes, Nicole Nevadunsky, Babak Edraki, Dirk Pikaart, William Lowery, Karim El-Sahwi, Peter E. Schwartz, Alessandro D. Santin. Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated survival analysis. Society of Gynecologic Oncology Annual Meeting, Toronto, Mar 28-31, 2020.
14. Klein KK, Goron AL, Taylor GH, **Roque DM**. Pap Smear outcomes in older HIV-positive women and HIV-negative matched controls. American Society for Colposcopy and Cervical Pathology Meeting on Anogenital & HPV-Related Diseases, Orlando, FL, Mar 31-Apr 03, 2020.
15. **Roque DM**, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader J, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. Scientific Plenary VI: Late Breaking Abstracts - Part 2. Society of Gynecologic Oncology Annual Meeting, Mar 19-25, 2021.

Oral Presentations-International

16. **Roque DM**, Bellone S, Buza N, Cocco E, Gasparrin Si, Rutherford TJ, Schwartz PE, Santin AD. Tubulin- β -III overexpression by uterine serous papillary carcinomas is a marker for poor overall survival, paclitaxel resistance, and sensitivity to epothilones. International Gynecologic Cancer Society, 14th Biennial Meeting, Vancouver, BC, October 13-16, 2012.
17. **Roque DM**, Bellone S, Buza N, Cocco E, Gasparrini S, Rutherford TJ, Schwartz PE, Santin AD. Increased tubulin- β -III expression in serous cancers following paclitaxel administration: implications for mechanisms of

- recurrent disease. Opening Plenary, International Gynecologic Cancer Society, 14th Biennial Meeting, Vancouver, BC, October 13-16, 2012. Plenary available at <http://webcasting.kenes.com/IGCS2012/>.
18. **Roque DM**, Schwab CL, English DP, Ratner ES, Silas DA, Azodi M, Rutherford T, Schwartz PE. Weekly ixabepilone with or without concurrent bevacizumab in the treatment of platinum/taxane-resistant endometrial and ovarian cancers: an institutional experience. Society for Gynecologic Investigation, 61st Annual Scientific Meeting, Florence, Italy, March 26-29, 2014.
 19. Santin AD, Nickles-Fader A, Siegel E, Buza N, Hui P, Abdelghany O, Silasi D, Chambers S, Secord A, LHavrilesky L, O'Malley D, Nevadunsky N, Edraki B, Pikaart D, Lowery W, El-Sahwi K, **Roque DM**, Schwartz PE. Phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinoma: results of interim analysis (NCT1367002). International Gynecologic Cancer Society, 16th Biennial Meeting, Lisbon, Portugal, October 29-31, 2016.
 20. Harper A, Legesse T, Reader J, Rao GG, Staats P, Fulton A, **Roque DM**. EP4 receptor and class III β -tubulin expression in uterine smooth muscle tumors: implications for prognosis and treatment. International Gynecologic Cancer Society, 16th Biennial Meeting, Lisbon, Portugal, October 29-31, 2016.
 21. **Roque DM**; Siegel ER; Buza N; Bellone S; Silasi DA; Huang GS; Andikyan V; Clark M; Azodi M; Schwartz PE; Rao GG; Reader J; Hui P; Tymon-Rosario JR; Harold J; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Santin AD. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. Society of Gynecologic Oncology Annual Meeting (virtual), Mar 19-25, 2021.

Poster Presentations

1. **Roque DM**, Hsu G, Beese L. Structural Studies of Telomerase. Howard Hughes Forum at Duke University, Durham, NC, April 2002.
2. Virador WV, **Roque DM**, Kassis J, Kohn EC. Differential BAG-3 binding and behavior of hsp70 and hsp27 by breast cancer cells. 8th Biennial Meeting on Molecular Chaperones and the Heat-Shock Response at Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, May 3-7, 2006.
3. **Roque DM**, Virador V, Kohn EC. Characterization of BAG-3 (bcl2-associated athanogene) cleavage products.
 - Post-baccalaureate Research Festival, National Institutes of Health, Bethesda, MD, May 24, 2006.
 - National Cancer Institute Center for Cancer Research 6th Annual Fellows and Young Investigators Retreat, Ocean City, MD, February 28-March 2, 2006.
4. **Roque DM**, Winters M, Aquino J, Nishizuka S, Kohn EC. Analysis of reverse-phase protein microarrays in clinical trials: a comparison of protein quantification using linear regression, logistic regression, and dose interpolation models.
 - American Association for Cancer Research, 97th Annual Meeting, Washington, DC, April 1-5, 2006.
 - American Medical Student Association, 56th Annual Convention, Chicago, IL, March 29-April 2, 2006.
 - Thirty-eighth Annual Student Research Day, University of North Carolina at Chapel Hill School of Medicine, January 25, 2006.
5. **Roque DM**, Mantia-Smaldone GM, Lenzner D, Zorn KK, Sukumvanich P, Kelley JL, Edwards RP. Biomarker and radiologic responses do not predict optimal interval debulking following neoadjuvant chemotherapy for advanced ovarian and primary peritoneal cancers. Society of Gynecologic Oncology, 41st Annual Meeting, San Francisco, CA, March 14-17, 2010.
6. **Roque DM**, Rungruang D, Thaller J, Vlad A, Mantia-Smaldone GM, Goldman H, Chu T, Zorn KK, Edwards RP. Intraperitoneal catheter aspirates can be used to monitor tumor microenvironment biomarkers. Society of Gynecologic Oncology, 41st Annual Meeting, San Francisco, CA, March 14-17, 2010.
7. **Roque DM**, Thaller JM, Vlad A, Edwards RP. Loco-regional immunity in patients undergoing intraperitoneal chemotherapy for advanced primary or recurrent epithelial ovarian cancers.
 - Translational Research Cancer Consortium, 14th Annual Meeting, Seven Springs, PA, February 24-26, 2011.
 - American Association for Cancer Research, 102nd Annual Meeting, Orlando, FL, April 2-6, 2011 (accepted but not presented).
8. **Roque DM**, Carrara L, Guzzo F, Bellone S, Cocco E Sartori E, Pecorelli S, Schwartz PE, Rutherford TJ, Santin AD. Differential *in vitro* sensitivity to paclitaxel versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin β -III expression. Society of Gynecologic Oncology, 43rd Annual Meeting, Austin, TX, March 24-27, 2012.

9. **Roque DM**, Bellone S, Betti M, Silasi DA, Ratner ER, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Mammaglobin B (SCGB2A-1)-specific CD8+ cytotoxic T lymphocytes are highly effective in killing autologous chemotherapy-resistant ovarian cancer cells: implications for SCGB2A-1 dendritic cell-based therapeutic vaccines. Society of Gynecologic Oncology, 43rd Annual Meeting, Austin, TX, March 24-27, 2012.
10. Cocco E, Bellone S, **Roque DM**, Guzzo F, Gasparrini S, Pecorelli S, Silasi DA, Azodi M, Ratner E, Rutherford TJ, Schwartz PE, Weller CE, Saltzman WM, Santin AD. *In vivo* targeting of CD44+ ovarian cancer stem cells (CSC) by Clostridium Perfringens Enterotoxin binding domain (CPE-peptide) conjugated to poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NP). American Association for Cancer Research, 103rd Annual Meeting, Chicago, IL, March 31-April 4, 2012. *Cancer Res* 2012;72(8 Suppl): abstract 364.
11. **Roque DM**, Ratner, E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.. Weekly ixabepilone with or without concurrent bevacizumab in the treatment of recurrent endometrial cancer. *J Clin Oncol* 30, 2012 (suppl; abstr e15526) [publication only].
12. **Roque DM**, Bellone S, Romani C, Buza N, Cocco E, Gasparrini S, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD. Tubulin- β -III overexpression is a marker of sensitivity to epothilones in ovarian clear cell carcinoma. International Gynecologic Cancer Society, 14th Biennial Meeting, Vancouver, BC, October 13-16, 2012.
13. **Roque DM**, Buza N, Glasgow M, Ratner ES, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Class III β -tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Society of Gynecologic Oncology, 44th Annual Meeting, Los Angeles, CA, March 9-13, 2013.
14. English DP, Schwab CL, **Roque DM**, Bellone S, Ratner ES, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ. Solitomab, an EpCAM/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines and fresh tumor ex vivo. Society of Gynecologic Oncology, 45th Annual Meeting, Tampa, FL, March 22-25, 2014.
15. **Roque DM**, Schwab CL, English DP, Ratner ES, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Weekly ixabepilone with or without concurrent bevacizumab in the treatment of platinum/taxane-resistant endometrial and ovarian cancers: an institutional experience. Society of Gynecologic Oncology, 45th Annual Meeting, Tampa, FL, March 22-25, 2014.
16. Schwab CL, **Roque DM**, English DP, Bellone S, Ratner ES, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Afatinib, an irreversible ErbB family blocker, demonstrates remarkable activity against HER2 amplified uterine serous endometrial cancer in vitro and in vivo. Society for Gynecologic Investigation, 61st Annual Scientific Meeting, Florence, Italy, March 26-29, 2014.
17. Black JD, **Roque DM**, Rutherford TJ, Schwartz PE, Ratner ES. Malignant degeneration of mature cystic teratomas. Society for Gynecologic Investigation, 61st Annual Scientific Meeting, Florence, Italy, March 26-29, 2014.
18. **Roque DM**, Varughese J, English DP, Gressel GM, Lundsberg L, Ratner ES, Rutherford TJ, Schwartz PE. Treatment of uterine carcinosarcoma with cisplatin/ifosfamide, paclitaxel/ifosfamide, or carboplatin/paclitaxel. Society for Gynecologic Investigation, 61st Annual Scientific Meeting, Florence, Italy, March 26-29, 2014.
19. Black JD, Lopez S, Bellone S, Schwab CL, English DP, **Roque DM**, Silasi DA, Ratner ES, M Azodi, Rutherford TJ, Schwartz PE, Santin AD. Mutations in the PIK3 pathway as a major determinant of trastuzumab resistance in uterine serous carcinoma. Society of Gynecologic Oncology 46th Annual Meeting, Chicago, IL, March 28-31, 2015.
20. Schwab CL, English DP, Black JB, Lopez S, Bellone D, **Roque DM**, Ratner ES, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Society of Gynecologic Oncology 46th Annual Meeting, Chicago, IL, March 28-31, 2015.
21. **Roque DM**, Schwab CL, Goloubeva O, English DP, Black JD, Silasi D, Azodi M, Rutherford TJ, Santin AD, Schwartz PE, Ratner ES. Choice of adjuvant chemotherapy following neoadjuvant carboplatin / paclitaxel and interval debulking. Society of Gynecologic Oncology, 46th Annual Meeting March 28-31, 2015.
22. Ramaseshan A, Felton J, **Roque DM**, Rao G, Sanses T. Pelvic floor disorders in women with gynecologic malignancies: a systematic review. American Urogynecologic Society, 36th Annual Scientific Meeting, Seattle, WA, Oct 13-17, 2015.
23. Reader J, Staats P, Goloubeva O, **Roque DM**, Maya Matheny, Amy M. Fulton, Gautam G. Rao. Functional studies of the prostaglandin E2 receptor EP4 in ovarian cancer. American Association for Cancer Research 107th Annual Meeting, New Orleans, LA, April 16-20, 2016.
24. Mohindra P, Bentzen S, Scartoni D, Giacomelli I, **Roque DM**, Gautam Rao, Nader Hanna, Elizabeth Nichols. Adjuvant therapy for locoregionally advanced endometrioid adenocarcinoma: upfront chemotherapy or

- upfront radiotherapy? American Society for Radiation Oncology, 58th Annual Meeting, Boston, MA, Sept 25-28, 2016.
25. Mohindra P, Bentzen S, Scartoni D, Giacomelli I, Rao D, **Roque DM**, Hanna N, Nichols E. Adjuvant whole pelvic radiation therapy for endometrioid adenocarcinoma: 45 Gy or 50/50.4 G? American Society for Radiation Oncology, 58th Annual Meeting, Boston, MA, Sept 25-28, 2016.
 26. Schillinger R, D'Emic N, Nichols E, Mohindra P, Pectasides M, Rao GG, **Roque DM**. Re-irradiation of locally recurrent gynecologic cancers: a single-institution experience. International Gynecologic Cancer Society, 16th Biennial Meeting, Lisbon, Portugal, October 29-31, 2016.
 27. Harper A, Cohen J, **Roque DM**, Rao GG, Mohindra P, Nichols E. Barriers to timely completion of radiation therapy in patients with cervical cancer in an urban tertiary care center. International Gynecologic Cancer Society, 16th Biennial Meeting, Lisbon, Portugal, October 29-31, 2016.
 28. **Roque DM**, Meir-Levi D, Rao GG, Staats PN, Fulton, Jocelyn Reader. EP4 receptor antagonism in paclitaxel-resistant ovarian clear cell carcinomas that overexpress class III β -tubulin. American Association for Cancer Research, Annual Meeting, Washington, DC, April 1-5, 2017.
 29. Fan C, Reader J, Rao G, Staats P, Ching M, Fulton A, **Roque DM**. EP4 receptor antagonism in paclitaxel-resistant ovarian clear cell carcinomas. AACR Addressing Critical Questions in Ovarian Cancer Research and Treatment, Pittsburgh, PA, October 1-4, 2017.
 30. Ching M, Fan C, **Roque DM**, Rao GG, Staats P, Fulton A, Reader J. Functional analysis of PGE2 pathway members MRP4 and EP4 in ovarian cancer. AACR Addressing Critical Questions in Ovarian Cancer Research and Treatment, Pittsburgh, PA, October 1-4, 2017.
 31. Fan C, Reader J, Ory E, Lee CJ, Vitolo MJ, Martin S, Rao GG, MD; Fulton A, Jewell C, **Roque DM**. Microtentacle composition and tubulin isotype among ovarian carcinomas. Annual Meeting of the Mid-Atlantic Gynecologic Oncology Society, Charleston, SC, October 19-20, 2017.
 32. **Roque DM**, Fan C, Ory E, Lee C, Vitolo M, Martin S, Rao GG, Fulton A, Ching M, Jewell C, Reader J. Microtentacle composition and tubulin isotype among ovarian carcinomas. Microtubules: from atoms to complex systems. European Molecular Biology Organization | European Molecular Biology Laboratory. Heidelberg, Germany, May 27-30, 2018.
 33. **Roque DM**, Fan C, Jasarevic E, MacKenzie M, Alexandrov I, Rao GG, Reader J. Serum exosome profiling reveals distinct phosphorylation biosignatures in cervical cancer: a pilot study. Society of Gynecologic Oncology 50th Annual Meeting, Hawaii, March 16-19, 2019.
 34. Mohindra P, Lamichhane N, Marter K, Krudys K, **Roque DM**, Rao G, Nichols E, Yi B. Robust optimization for gynecological high-dose rate interstitial brachytherapy using post-hoc uniformity correction. *Brachytherapy* 2019; May-June 18(3):S99-100.
 35. Wu S, Reader J, Fan C, Ory E, **Roque DM**, Fulton A. Molecular and structural characterization of low-grade serous ovarian cancer. Summer Research Training Programs Student Research Forum, Baltimore, MD, August 1, 2019.
 36. Klein K, Goron A, Taylor G, **Roque DM**. Pap smear outcomes in HIV-positive women >65 years and HIV-negative matched controls. Mid-Atlantic Gynecologic Oncology Society 2019 Annual Meeting, Charlotte, NC, Oct 24-26, 2019.
 37. Helou C, Seal P, Sanses T, Morozov V, **Roque DM**. Training, Education for Robotic Performance with Simulation (TERPS): a valuable tool for Gynecologic Surgeons in Training. American Association of Gynecologic Laparoscopists 48th Global Congress on Minimally Invasive Gynecologic Surgery, Vancouver, BC, Nov 9-13, 2019.
 38. Sorrin A, Reader J, Najafali D, Liang BJ, Baglo Y, **Roque DM**, Huang HC. Photodynamic priming to attenuate ovarian cancer cell migration. SPIE Photonics West, San Francisco, Feb 1-6, 2020.
 39. Dorismund V, **Roque DM**, Bui B, Sanses T. Training Education for Robotic Performance with Simulation (TERPS): maintenance of certification for robotic surgeons. Society of Gynecologic Surgeons Annual Scientific Meeting, Jacksonville, FL, Mar 29-Apr 1, 2020.
 40. Klein K, A Goron, Taylor G, **Roque DM**. Pap smear outcomes in HIV-positive women \geq 65 years and HIV-negative matched controls. Society of Gynecologic Oncology Annual Meeting, Toronto, Mar 28-31, 2020.
 41. **Roque DM**, Reader J, Sorrin A, Huang HC. Photoimmunoconjugate nanoparticle, mechanism-based therapy for intraperitoneal treatment of carcinomatosis. Society of Gynecologic Oncology Annual Meeting, Toronto, Mar 28-31, 2020 (featured poster).
 42. Dandulakis M, Reader J, Smith P, Fan C, Carey M, Lin J, Liang Xu, Legesse T, Ioffe O, Rao G, Fulton A, **Roque DM**. HuR inhibition is a novel approach to treatment of chemotherapy-resistant low-grade serous ovarian carcinomas. Society for Gynecologic Oncology Annual Meeting, Toronto, Mar 28-31, 2020.

43. Yoder AK, Wang S, Manetta S, **Roque DM**, Son C, Chiao E, Ludwig MS, Levinson K, Lin LL. Cervical cancer outcomes in women living with HIV in the age of anti-retroviral therapy. American Society for Radiation Oncology Annual Meeting Miami Beach, FL, October 25-28, 2020.
44. Mohindra P, Pollock AE, Patel AN, **Roque DM**, Rao G, Nichols EM. First clinical experience of quality assurance CT scan adapted intensity modulated proton therapy for utero-cervical cancers. American Society for Radiation Oncology Annual Meeting Miami Beach, FL, October 25-28, 2020.
45. **Roque DM**, Bellone S, Siegel ER, Buza, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Schwartz PE, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin JA, Choi J, Santin A. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high endometrial cancer patients with Lynch-like vs MLH-1 methylated characteristics (NCT02899793). American Society of Clinical Oncology Annual Meeting Jun 4-8, 2021 (poster discussion).

Published Multimedia

1. Wong-You-Cheong, J & **Roque DM**. Tubal ectopic pregnancy. Case Collections: Radiologic Society of North America. Available at <https://cases.rsna.org/author/view/9137ad86-ef43-48cf-ab8f-323ed9ffd8f0>.